Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 22, 2024American Journal of HematologyOpen Access

miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype

View Full Paper
Ask AI
Bookmark
Share

Authors

ECErnesto José Cuenca‐ZamoraInstituto de Salud Carlos IIIPGPedro Jesús Guijarro-CarrilloCentro Regional de HemodonaciónMLMaría José López-PovedaHospital General Universitario Morales Meseguer

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cuenca‐Zamora et al. (2024) studied this question.

synapsesocial.com/papers/68e6e1d5b6db64358765d2cchttps://doi.org/10.1002/ajh.27322
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NF-κB signaling in inflammation2017 · 8,590 citations
  2. 2Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms2018 · 9 citations
  3. 3Bone marrow–specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis2018 · 31 citations
  4. 4Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management2023 · 307 citations
  5. 5JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis2012 · 1,836 citations